Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 5/20 | 0.48 |
| ▸ | FEN1 | P39748 | 5/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247109 | 0.86 | ALDH1A1 (0.47) | ALOX5APFEN1KCNQ3KCNQ2 | |
| SCHEMBL252272 | 0.77 | ALK (0.47) | ALOX5APFEN1P2RX3 | |
| SCHEMBL25000951 | 0.72 | P2RX3 (0.40) | ALOX5APFEN1KCNQ3KCNQ2P2RX3 | |
| SCHEMBL16574085 | 0.71 | KCNQ3 (0.39) | ALOX5APFEN1KCNQ3KCNQ2P2RX3 | |
| SCHEMBL27440493 | 0.71 | PDGFRB (0.49) | KCNQ3KCNQ2 | |
| SCHEMBL30630871 | 0.71 | PDGFRB (0.49) | KCNQ3KCNQ2 | |
| SCHEMBL15308524 | 0.70 | ALOX5AP (0.47) | ALOX5APFEN1KCNQ3KCNQ2S1PR1 | |
| SCHEMBL12591809 | 0.69 | NAAA (0.43) | ALOX5APFEN1KCNQ3KCNQ2FFAR4 | |
| SCHEMBL17657954 | 0.69 | ALOX5AP (0.46) | ALOX5APFEN1KCNQ3KCNQ2MAP4K4 | |
| SCHEMBL2229809 | 0.68 | ALDH1A1 (0.42) | ALOX5APFEN1KCNQ3KCNQ2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | ALOX5AP 426/4885FEN1 4863/4885KCNQ3 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.